Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine
Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese
population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset
Seizures (POS).